hemoglobin A1c

hemoglobin A1c. It is a form of hemoglobin that is chemically linked to glucose, formed through a non-enzymatic process known as the Maillard reaction. The test, pioneered by researcher Samuel Rahbar, measures the percentage of glycated hemoglobin in the blood, providing a reliable indicator of average blood glucose levels over the preceding two to three months. Its adoption as a cornerstone of diabetes mellitus management was significantly advanced through landmark studies like the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study.

Biochemistry and formation

The formation of this analyte is a continuous, post-translational modification resulting from the non-enzymatic binding of glucose to the N-terminal valine of the beta chain of the hemoglobin molecule. This irreversible process, a type of glycation, occurs at a rate proportional to the concentration of glucose in the blood plasma over the 120-day lifespan of a red blood cell. The initial Schiff base adduct rearranges to form a stable ketoamine linkage, creating the definitive molecule. The rate of this reaction is influenced by factors such as blood pH and the presence of certain enzymes, though it is distinct from enzymatic glycosylation processes seen in other proteins.

Clinical significance

Its primary clinical significance lies in its strong predictive value for the long-term complications of diabetes mellitus. Elevated levels are correlated with an increased risk for diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy, as conclusively demonstrated by the Diabetes Control and Complications Trial. It serves as a critical diagnostic criterion, with organizations like the American Diabetes Association and the World Health Organization defining specific thresholds for the diagnosis of diabetes. Furthermore, it is used to assess the risk of cardiovascular disease in both diabetic and non-diabetic populations, linking chronic hyperglycemia to macrovascular events.

Measurement and interpretation

Measurement is performed using various methodologies, including high-performance liquid chromatography, immunoassay, and capillary electrophoresis, with standardization efforts led by the National Glycohemoglobin Standardization Program. Results are reported as a percentage of total hemoglobin or, increasingly, in units of mmol/mol as per the International Federation of Clinical Chemistry system. Interpretation requires understanding that the result reflects an average glucose; for example, a result of 7% corresponds roughly to an average blood glucose of 154 mg/dL (8.6 mmol/L), a relationship established by the A1C-Derived Average Glucose study. Laboratories must be certified by programs like the College of American Pathologists to ensure accuracy.

Factors affecting HbA1c levels

While primarily reflecting glycemia, levels can be affected by conditions that alter red blood cell turnover or hemoglobin structure. For instance, hemolytic anemia, sickle cell disease, and recent blood transfusion can falsely lower values due to shortened erythrocyte lifespan. Conversely, iron deficiency anemia and asplenia may elevate it. Genetic variants like hemoglobin C or hemoglobin S can interfere with some assay methods, necessitating alternative tests such as fructosamine measurement. Other factors include pregnancy, chronic kidney disease, and the use of certain medications like dapsone or high-dose vitamin E.

Use in diabetes management

In clinical practice, it is the gold standard for evaluating the efficacy of glycemic management over time. Treatment guidelines from the American Diabetes Association recommend a target generally below 7% for most non-pregnant adults, with individualized goals set by the healthcare team. It is used to guide therapy adjustments, including intensification of insulin regimens or the initiation of additional agents like SGLT2 inhibitors or GLP-1 receptor agonists. The test is integral to structured management programs like the Chronic Care Model and is a key performance measure for healthcare systems and insurers, including the Centers for Medicare & Medicaid Services.

Category:Blood tests Category:Diabetes